Search

Your search keyword '"Dell'Aquila E"' showing total 156 results
Start Over Author "Dell'Aquila E" Search Limiters Full Text
156 results on '"Dell'Aquila E"'

1. Surface operators, dual quivers and contours

Author

Ashok, S. K., Ballav, S., Billo', M., Dell'Aquila, E., Frau, M., Gupta, V., John, R. R., and Lerda, A.

Subjects
High Energy Physics - Theory
Abstract

We study half-BPS surface operators in four dimensional N=2 SU(N) gauge theories, and analyze their low-energy effective action on the four dimensional Coulomb branch using equivariant localization. We also study surface operators as coupled 2d/4d quiver gauge theories with an SU(N) flavour symmetry. In this description, the same surface operator can be described by different quivers that are related to each other by two dimensional Seiberg duality. We argue that these dual quivers correspond, on the localization side, to distinct integration contours that can be determined by the Fayet-Iliopoulos parameters of the two dimensional gauge nodes. We verify the proposal by mapping the solutions of the twisted chiral ring equations of the 2d/4d quivers onto individual residues of the localization integrand., Comment: 42 pages. v2: Sections 4 and 5 partially restructured in order to describe in a more compact ad unified way the association of contours to quivers

Published
2018
Full Text
View/download PDF

2. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

Author

Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., and Santini, D.

Published
2022
Full Text
View/download PDF

3. Surface operators in 5d gauge theories and duality relations

Author

Ashok, S. K., Billo, M., Dell'Aquila, E., Frau, M., Gupta, V., John, R. R., and Lerda, A.

Subjects
High Energy Physics - Theory
Abstract

We study half-BPS surface operators in 5d N=1 gauge theories compactified on a circle. Using localization methods and the twisted chiral ring relations of coupled 3d/5d quiver gauge theories, we calculate the twisted chiral superpotential that governs the infrared properties of these surface operators. We make a detailed analysis of the localization integrand, and by comparing with the results from the twisted chiral ring equations obtain constraints on the 3d and 5d Chern-Simons levels so that the instanton partition function does not depend on the choice of integration contour. For these values of the Chern-Simons couplings, we comment on how the distinct quiver theories that realize the same surface operator are related to each other by Aharony-Seiberg dualities., Comment: 39 pages. v2: A few sentences rephrased, references added, and typos corrected. Matches version published in JHEP

Published
2017
Full Text
View/download PDF

4. Surface operators, chiral rings, and localization in N=2 gauge theories

Author

Ashok, S. K., Billo, M., Dell'Aquila, E., Frau, M., Gupta, V., John, R. R., and Lerda, A.

Subjects
High Energy Physics - Theory
Abstract

We study half-BPS surface operators in supersymmetric gauge theories in four and five dimensions following two different approaches. In the first approach we analyze the chiral ring equations for certain quiver theories in two and three dimensions, coupled respectively to four- and five-dimensional gauge theories. The chiral ring equations, which arise from extremizing a twisted chiral superpotential, are solved as power series in the infrared scales of the quiver theories. In the second approach we use equivariant localization and obtain the twisted chiral superpotential as a function of the Coulomb moduli of the four- and five-dimensional gauge theories, and find a perfect match with the results obtained from the chiral ring equations. In the five-dimensional case this match is achieved after solving a number of subtleties in the localization formulas which amounts to choosing a particular residue prescription in the integrals that yield the Nekrasov-like partition functions for ramified instantons. We also comment on the necessity of including Chern-Simons terms in order to match the superpotentials obtained from dual quiver descriptions of a given surface operator., Comment: 41 pages. v3: typos corrected in the text and in some formulae. Some sentences rephrased according to the suggestions of the referee. Matches the version published on JHEP

Published
2017
Full Text
View/download PDF

5. Modular and duality properties of surface operators in N=2* gauge theories

Author

Ashok, S. K., Billo, M., Dell'Aquila, E., Frau, M., John, R. R., and Lerda, A.

Subjects
High Energy Physics - Theory
Abstract

We calculate the instanton partition function of the four-dimensional N=2* SU(N) gauge theory in the presence of a generic surface operator, using equivariant localization. By analyzing the constraints that arise from S-duality, we show that the effective twisted superpotential, which governs the infrared dynamics of the two-dimensional theory on the surface operator, satisfies a modular anomaly equation. Exploiting the localization results, we solve this equation in terms of elliptic and quasi-modular forms which resum all non-perturbative corrections. We also show that our results, derived for monodromy defects in the four-dimensional theory, match the effective twisted superpotential describing the infrared properties of certain two-dimensional sigma models coupled either to pure N=2 or to N=2* gauge theories., Comment: 51 pages, v3: references added, typos fixed, footnote added, some small changes in the text, appendix B streamlined. Matches the published version

Published
2017
Full Text
View/download PDF

6. Chiral observables and S-duality in N = 2* U(N) gauge theories

Author

Ashok, S. K., Billo, M., Dell'Aquila, E., Frau, M., Lerda, A., Moskovic, M., and Raman, M.

Subjects
High Energy Physics - Theory
Abstract

We study N = 2* theories with gauge group U(N) and use equivariant localization to calculate the quantum expectation values of the simplest chiral ring elements. These are expressed as an expansion in the mass of the adjoint hypermultiplet, with coefficients given by quasi-modular forms of the S-duality group. Under the action of this group, we construct combinations of chiral ring elements that transform as modular forms of definite weight. As an independent check, we confirm these results by comparing the spectral curves of the associated Hitchin system and the elliptic Calogero-Moser system. We also propose an exact and compact expression for the 1-instanton contribution to the expectation value of the chiral ring elements., Comment: 37 pages

Published
2016
Full Text
View/download PDF

7. S-duality, triangle groups and modular anomalies in N=2 SQCD

Author

Ashok, S. K., Dell'Aquila, E., Lerda, A., and Raman, M.

Subjects
High Energy Physics - Theory
Abstract

We study N = 2 superconformal theories with gauge group SU(N) and 2N fundamental flavours in a locus of the Coulomb branch with a Z_N symmetry. In this special vacuum, we calculate the prepotential, the dual periods and the period matrix using equivariant localization. When the flavours are massless, we find that the period matrix is completely specified by [N/2] effective couplings. On each of these, we show that the S-duality group acts as a generalized triangle group and that its hauptmodul can be used to write a non-perturbatively exact relation between each effective coupling and the bare one. For N = 2, 3, 4 and 6, the generalized triangle group is an arithmetic Hecke group which contains a subgroup that is also a congruence subgroup of the modular group PSL(2,Z). For these cases, we introduce mass deformations that respect the symmetries of the special vacuum and show that the constraints arising from S-duality make it possible to resum the instanton contributions to the period matrix in terms of meromorphic modular forms which solve modular anomaly equations., Comment: 50 pages, 1 figure; a few references added; to be published in JHEP

Published
2016
Full Text
View/download PDF

8. Modular anomaly equations and S-duality in N=2 conformal SQCD

Author

Ashok, S. K., Billó, M., Dell'Aquila, E., Frau, M., Lerda, A., and Raman, M.

Subjects
High Energy Physics - Theory
Abstract

We use localization techniques to study the non-perturbative properties of an N=2 superconformal gauge theory with gauge group SU(3) and six fundamental flavours. The instanton corrections to the prepotential, the dual periods and the period matrix are calculated in a locus of special vacua possessing a Z_3 symmetry. In a semi-classical expansion, we show that these observables are constrained by S-duality via a modular anomaly equation which takes the form of a recursion relation. The solutions of the recursion relation are quasi-modular functions of Gamma_1(3), which is a subgroup of the S-duality group and is also a congruence subgroup of SL(2,Z)., Comment: 30 pages, 2 figures, references added, typos fixed

Published
2015

9. Non-perturbative studies of N=2 conformal quiver gauge theories

Author

Ashok, S. K., Billó, M., Dell'Aquila, E., Frau, M., John, R. R., and Lerda, A.

Subjects
High Energy Physics - Theory
Abstract

We study N=2 super-conformal field theories in four dimensions that correspond to mass-deformed linear quivers with n gauge groups and (bi-)fundamental matter. We describe them using Seiberg-Witten curves obtained from an M-theory construction and via the AGT correspondence. We take particular care in obtaining the detailed relation between the parameters appearing in these descriptions and the physical quantities of the quiver gauge theories. This precise map allows us to efficiently reconstruct the non-perturbative prepotential that encodes the effective IR properties of these theories. We give explicit expressions in the cases n=1,2, also in the presence of an Omega-background in the Nekrasov-Shatashvili limit. All our results are successfully checked against those of the direct microscopic evaluation of the prepotential a la Nekrasov using localization methods., Comment: 56 pages, 7 figures, PdfLaTeX. v2: a few references added, version to appear on Fortschritte der Physik

Published
2015
Full Text
View/download PDF

10. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

Author

Marmorino, F., Rossini, D., Lonardi, S., Moretto, R., Zucchelli, G., Aprile, G., Dell’Aquila, E., Ratti, M., Bergamo, F., Masi, G., Urbano, F., Ronzoni, M., Libertini, M., Borelli, B., Randon, G., Buonadonna, A., Allegrini, G., Pella, N., Ricci, V., Boccaccino, A., Latiano, T.P., Cordio, S., Passardi, A., Tamburini, E., Boni, L., Falcone, A., and Cremolini, C.

Published
2019
Full Text
View/download PDF

11. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Author

Dell’Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., Tonini, G., Tomcikova, D., Boni, L., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

13. 398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment

Author

Signorelli, C., primary, Schirripa, M., additional, Chilelli, M.G., additional, Calegari, M.A., additional, Basso, M., additional, Anghelone, A., additional, Lucchetti, J., additional, Minelli, A., additional, Angotti, L., additional, Morelli, C., additional, Dell'Aquila, E., additional, Cosimati, A., additional, Gemma, D., additional, Ribelli, M., additional, Corsi, D.C., additional, Arrivi, G., additional, Zoratto, F., additional, Morandi, M.G., additional, Santamaria, F., additional, Saltarelli, R., additional, and Ruggeri, E.M., additional

Published
2022
Full Text
View/download PDF

16. P-42 Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorectal cancer: A retrospective cohort study

Author

Rosati, G., primary, Corsi, D., additional, Avallone, A., additional, Brugnatelli, S., additional, Dell'Aquila, E., additional, Pella, N., additional, Cappetta, A., additional, Cicero, G., additional, Carlomagno, C., additional, Colombo, A., additional, Rapisardi, S., additional, Pinto, C., additional, Cantore, M., additional, Germano, D., additional, and Reggiardo, G., additional

Published
2021
Full Text
View/download PDF

17. 617P Predictive and prognostic impact of primary tumor location on sequential treatment with regorafenib and trifluridine/tipiracil at third line and beyond in metastatic colorectal cancer: A real-world multicenter retrospective analysis

Author

Signorelli, C., Calegari, M.A., Basso, M., Anghelone, A., Lucchetti, J., Minelli, A., Angotti, L., Zurlo, I.V., Schirripa, M., Chilelli, M.G., Morelli, C., Dell'Aquila, E., Gemma, D., Ribelli, M., Arrivi, G., Zoratto, F., Morandi, M.G., Santamaria, F., Saltarelli, R., and Ruggeri, E.M.

Published
2023
Full Text
View/download PDF

18. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Author

Loupakis F., Intini R., Cremolini C., Orlandi A., Sartore-Bianchi A., Pietrantonio F., Pella N., Spallanzani A., Dell'Aquila E., Scartozzi M., De Luca E., Rimassa L., Formica V., Leone F., Calvetti L., Aprile G., Antonuzzo L., Urbano F., Prenen H., Negri F., Di Donato S., Buonandi P., Tomasello G., Avallone A., Zustovich F., Moretto R., Antoniotti C., Salvatore L., Calegari M. A., Siena S., Morano F., Ongaro E., Cascinu S., Santini D., Ziranu P., Schirripa M., Buggin F., Prete A. A., Depetris I., Biason P., Lonardi S., Zagonel V., Fassan M., Di Maio M., Loupakis, F., Intini, R., Cremolini, C., Orlandi, A., Sartore-Bianchi, A., Pietrantonio, F., Pella, N., Spallanzani, A., Dell'Aquila, E., Scartozzi, M., De Luca, E., Rimassa, L., Formica, V., Leone, F., Calvetti, L., Aprile, G., Antonuzzo, L., Urbano, F., Prenen, H., Negri, F., Di Donato, S., Buonandi, P., Tomasello, G., Avallone, A., Zustovich, F., Moretto, R., Antoniotti, C., Salvatore, L., Calegari, M. A., Siena, S., Morano, F., Ongaro, E., Cascinu, S., Santini, D., Ziranu, P., Schirripa, M., Buggin, F., Prete, A. A., Depetris, I., Biason, P., Lonardi, S., Zagonel, V., Fassan, M., and Di Maio, M.

Subjects
Adult, Male, Proto-Oncogene Proteins B-raf, Scoring system, DNA Mutational Analysis, Metastases, V600E, BRAF, Colorectal cancer, Prognostic markers, Risk Assessment, Young Adult, Predictive Value of Tests, Risk Factors, Biomarkers, Tumor, Humans, Genetic Predisposition to Disease, Neoplasm Metastasis, Aged, Retrospective Studies, Aged, 80 and over, Middle Aged, Prognosis, Phenotype, Italy, Mutation, Female, Colorectal Neoplasms
Abstract

Background: Despite the well-known negative prognostic value of the V600EBRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined. Methods: Two large retrospective series of V600EBRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. The model was internally and externally validated. Results: A total of 395 V600EBRAF-mutated mCRCs were included in the exploratory set. Performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). Two different scoring systems were built: a ‘complete’ score (0–16) including all significant covariates and a ‘simplified’ score (0–9), based only on clinicopathological covariates, and excluding laboratory values. Adopting the complete score, proportions of patients with a low (0–4), intermediate (5–8) and high (9–16) score were 44.7%, 42.6% and 12.6%, respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44–3.22, p < .001) and 6.6 months (HR for high vs low risk: 4.72, 95% CI: 2.72–8.20, p < .001). Similar results were observed also after adjusting for the type of first-line treatment and adopting the simplified score. The simplified prognostic score derived from the exploratory set was then applied to the validation set for external confirmation. Conclusions: These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy. These tools could be useful in clinical practice, would allow better stratification of patients in clinical trials and may be adopted for proper adjustments in exploratory translational analyses.

Published
2019

21. P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study

Author

Signorelli, C., Calegari, M., Basso, M., Anghelone, A., Lucchetti, J., Minelli, A., Angotti, L., Zurlo, I., Schirripa, M., Chilelli, M., Morelli, C., Dell’Aquila, E., Cosimati, A., Gemma, D., Ribelli, M., Corsi, D., Arrivi, G., Zoratto, F., Morandi, M., Santamaria, F., Saltarelli, R., and Ruggeri, E.

Published
2023
Full Text
View/download PDF

22. P-168 Second-line, anti-VEGF based after first-line, anti-EGFR based treatment in RAS wild-type metastatic colorectal cancer: The multicenter, retrospective, real-life SLAVE study

Author

Parisi, A., primary, Camarda, F., additional, Ribelli, M., additional, Rossini, D., additional, Germani, M., additional, Dell'Aquila, E., additional, Natoli, C., additional, Pietro, D., additional, Corsi, D., additional, Zurlo, I., additional, Lombardi, P., additional, Zanaletti, N., additional, Giampieri, R., additional, Merloni, F., additional, Occhipinti, M., additional, Marchetti, P., additional, Roberto, M., additional, Mazzuca, F., additional, Ghidini, M., additional, Garajová, I., additional, Zoratto, F., additional, and Ficorella, C., additional

Published
2020
Full Text
View/download PDF

23. P-217 Value of liquid biopsy using high-affinity plasma DNA binding magnetic beads and qualitative real-time PCR for KRAS, NRAS and BRAF mutations in metastatic colorectal cancer patients

Author

Lucchetti, J., primary, Formica, V., additional, Doldo, E., additional, Morelli, C., additional, Vergilii, L., additional, Nitti, D., additional, Nardecchia, A., additional, Renzi, N., additional, Dell'Aquila, E., additional, Perrone, G., additional, Palmieri, G., additional, Orlandi, A., additional, and Roselli, M., additional

Published
2020
Full Text
View/download PDF

25. P-161 Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

Author

Vivolo, R., primary, Bria, E., additional, Zurlo, I., additional, Bensi, M., additional, Dell'Aquila, E., additional, Anghelone, A., additional, Corsi, D., additional, Caira, G., additional, Santini, D., additional, Ingrosso, D., additional, Emiliani, A., additional, Calegari, M., additional, Citarella, F., additional, Pozzo, C., additional, Grande, R., additional, Basso, M., additional, Tortora, G., additional, and Salvatore, L., additional

Published
2020
Full Text
View/download PDF

27. Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO

Author

Dell’Aquila, E., primary, Rossini, D., additional, Stellato, M., additional, Bergamo, F., additional, Aprile, G., additional, Morano, F., additional, Intini, R., additional, Fea, E., additional, Ronzoni, M., additional, Libertini, M., additional, Buonadonna, A., additional, Fanchini, L., additional, Marcucci, L., additional, Maiello, E., additional, Marmorino, F., additional, Boccaccino, A., additional, Cordio, S., additional, Masi, G., additional, Falcone, A., additional, and Santini, D., additional

Published
2019
Full Text
View/download PDF

28. Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis

Author

Rossini, D., primary, Pagani, F., additional, Pellino, A., additional, Dell’Aquila, E., additional, Liscia, N., additional, Bensi, M., additional, Germani, M., additional, Masi, G., additional, Moretto, R., additional, Santini, D., additional, Salvatore, L., additional, Scartozzi, M., additional, Lonardi, S., additional, Zucchelli, G., additional, Puglisi, F., additional, Vannini, F., additional, Colombo, C., additional, Falcone, A., additional, Pietrantonio, F., additional, and Cremolini, C., additional

Published
2019
Full Text
View/download PDF

29. A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy

Author

Parisi, A., primary, Cortellini, A., additional, Roberto, M., additional, Venditti, O., additional, Santini, D., additional, Dell’Aquila, E., additional, Stellato, M., additional, Marchetti, P., additional, Occhipinti, M., additional, Zoratto, F., additional, Mazzuca, F., additional, Tinari, N., additional, De Tursi, M., additional, Iezzi, L., additional, Natoli, C., additional, Ratti, M., additional, Pizzo, C., additional, Ghidini, M., additional, Ficorella, C., additional, and Cannita, K., additional

Published
2019
Full Text
View/download PDF

30. Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies

Author

Zucchelli, G., primary, Marmorino, F., additional, Rossini, D., additional, Aprile, G., additional, Casagrande, M., additional, Lonardi, S., additional, Murgioni, S., additional, Dell’Aquila, E., additional, Tomasello, G., additional, Moretto, R., additional, Antoniotti, C., additional, Borelli, B., additional, Urbano, F., additional, Ronzoni, M., additional, Zaniboni, A., additional, Manglaviti, S., additional, Buonadonna, A., additional, Ritorto, G., additional, Masi, G., additional, Allegrini, G., additional, Falcone, A., additional, and Cremolini, C., additional

Published
2019
Full Text
View/download PDF

31. Activity and safety of cetuximab plus modified folfoxiri followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer a randomized phase 2 clinical trial

Author

Cremolini, C., Antoniotti, C., Lonardi, S., Aprile, G., Bergamo, F., Masi, G., Grande, R., Tonini, G., Mescoli, C., Cardellino, G. G., Coltelli, L., Salvatore, Lisa, Corsi, Domenico Cristiano, Lupi, C., Gemma, D., Ronzoni, M., Dell'Aquila, E., Marmorino, F., Di Fabio, F., Mancini, M. L., Marcucci, L., Fontanini, G., Zagonel, V., Boni, L., Falcone, A., Salvatore L., Corsi D. C., Cremolini, C., Antoniotti, C., Lonardi, S., Aprile, G., Bergamo, F., Masi, G., Grande, R., Tonini, G., Mescoli, C., Cardellino, G. G., Coltelli, L., Salvatore, Lisa, Corsi, Domenico Cristiano, Lupi, C., Gemma, D., Ronzoni, M., Dell'Aquila, E., Marmorino, F., Di Fabio, F., Mancini, M. L., Marcucci, L., Fontanini, G., Zagonel, V., Boni, L., Falcone, A., Salvatore L., and Corsi D. C.

Abstract

IMPORTANCE The combination of a triple-drug chemotherapy regimen with an anti–epidermal growth factor receptor (EGFR) agent as a first-line treatment of metastatic colorectal cancer (mCRC) showed promising activity along with safety concerns in single-arm phase 2 trials. The role of maintenance following chemotherapy and anti-EGFR and the optimal regimen to be adopted are not established. OBJECTIVES To evaluate the activity and safety of cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) and explore the role of maintenance with cetuximab or bevacizumab in RAS and BRAF wild-type mCRC. DESIGN, SETTING, AND PARTICIPANTS In a prospective, noncomparative, open-label, multicenter, randomized phase 2 trial, patients aged 18 to 75 years with unresectable, previously untreated RAS and BRAF wild-type (before amendment, KRAS wild-type) mCRC were recruited from 21 oncology units in Italy from October 19, 2011, to March 1, 2015 (followed up through May 31, 2017). In total, 323 patients were screened and 143 were randomized to 2 treatment arms to receive as a first-line induction a regimen of mFOLFOXIRI plus cetuximab followed by cetuximab (arm A) or bevacizumab (arm B) until disease progression. Primary analyses were conducted in a modified intention-to-treat population. INTERVENTIONS mFOLFOXIRI plus cetuximab repeated every 2 weeks for up to 8 cycles, followed by maintenance with cetuximab or bevacizumab until disease progression. MAIN OUTCOMES AND MEASURES The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events. RESULTS Of 143 patients randomized, 116 (81.1%) (median [interquartile range (IQR)] age, 59.5 [53-67] years; 34 [29.3%] women) had RAS and BRAF wild-type mCRC. At a median (IQR) follow-up of 44.0 (30.5-52.1) months, 10-month PFRs were 50.8% (90% CI, 39.5%-62.2%) in arm A and 40.4% (90% CI, 29.4%-52.1%) in arm B. The overall respon

Published
2018

32. Surface operators, chiral rings and localization in N = 2 gauge theories

Author

Ashok, S. K., Billo', M., Dell'Aquila, E., Frau, M., Gupta, V., John, R. R., and Lerda, A.

Subjects
Extended Supersymmetry, Supersymmetry and Duality, Supersymmetry and Duality, Duality in Gauge Field Theories, Extended Supersymmetry, Duality in Gauge Field Theories
Published
2017

33. FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO

Author

Marmorino, F., primary, Cremolini, C., additional, Bergamo, F., additional, Pella, N., additional, Antoniotti, C., additional, Rossini, D., additional, Dell'Aquila, E., additional, Masi, G., additional, Salvatore, L., additional, Loupakis, F., additional, Marcucci, L., additional, Gemma, D., additional, Cardellino, G., additional, Borelli, B., additional, Ricci, V., additional, Delfanti, S., additional, Mori, E., additional, Tonini, G., additional, Lonardi, S., additional, Fontanini, G., additional, Boni, L., additional, and Falcone, A., additional

Published
2018
Full Text
View/download PDF

34. Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

Author

Rossini, D., primary, Cremolini, C., additional, Conca, E., additional, Del Re, M., additional, Busico, A., additional, Pietrantonio, F., additional, Bergamo, F., additional, Danesi, R., additional, Cardellino, G., additional, Tamburini, E., additional, Dell'Aquila, E., additional, Strippoli, A., additional, Masi, G., additional, Tonini, G., additional, Negri, F., additional, Corsi, D., additional, Pella, N., additional, Intini, R., additional, Falcone, A., additional, and Santini, D., additional

Published
2018
Full Text
View/download PDF

35. Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial

Author

Dell'Aquila, E., primary, Pantano, F., additional, Rossini, D., additional, Stellato, M., additional, Lonardi, S., additional, Masi, G., additional, Schirripa, M., additional, Marmorino, F., additional, Antoniotti, C., additional, Murgioni, S., additional, Tomasello, G., additional, Ronzoni, M., additional, Racca, P., additional, Vincenzi, B., additional, Allegrini, G., additional, Urbano, F., additional, Buonadonna, A., additional, Banzi, M., additional, Tonini, G., additional, Cremolini, C., additional, Falcone, A., additional, and Santini, D., additional

Published
2018
Full Text
View/download PDF

37. Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO

Author

Santini, D., primary, Cremolini, C., additional, Salvatore, L., additional, Lonardi, S., additional, Dell'Aquila, E., additional, Cattaneo, M., additional, Loupakis, F., additional, Rossini, D., additional, Vincenzi, B., additional, Ziampiri, S., additional, Buoro, V., additional, Tamburini, E., additional, Basile, D., additional, Corsi, D.C., additional, Fioroni, I., additional, Masi, G., additional, Borelli, B., additional, Del Re, M., additional, Tonini, G., additional, and Falcone, A., additional

Published
2017
Full Text
View/download PDF

40. PD-027 - Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis

Author

Rossini, D., Pagani, F., Pellino, A., Dell’Aquila, E., Liscia, N., Bensi, M., Germani, M., Masi, G., Moretto, R., Santini, D., Salvatore, L., Scartozzi, M., Lonardi, S., Zucchelli, G., Puglisi, F., Vannini, F., Colombo, C., Falcone, A., Pietrantonio, F., and Cremolini, C.

Published
2019
Full Text
View/download PDF

42. FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD)

Author

Casagrande, M., primary, Cremolini, C., additional, Zucchelli, G., additional, Bergamo, F., additional, Ferrari, L., additional, Pietrantonio, F., additional, Lonardi, S., additional, Loupakis, F., additional, Masi, G., additional, Pella, N., additional, Intini, R., additional, Salvatore, L., additional, Tomasello, G., additional, Pagani, F., additional, Pellino, A., additional, Dell'Aquila, E., additional, Ginocchi, L., additional, Milione, M., additional, Fea, E., additional, Pellegrinelli, A., additional, and Falcone, A., additional

Published
2016
Full Text
View/download PDF

44. P-237 - Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial

Author

Dell'Aquila, E., Pantano, F., Rossini, D., Stellato, M., Lonardi, S., Masi, G., Schirripa, M., Marmorino, F., Antoniotti, C., Murgioni, S., Tomasello, G., Ronzoni, M., Racca, P., Vincenzi, B., Allegrini, G., Urbano, F., Buonadonna, A., Banzi, M., Tonini, G., Cremolini, C., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

45. O-017 - FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO

Author

Marmorino, F., Cremolini, C., Bergamo, F., Pella, N., Antoniotti, C., Rossini, D., Dell'Aquila, E., Masi, G., Salvatore, L., Loupakis, F., Marcucci, L., Gemma, D., Cardellino, G., Borelli, B., Ricci, V., Delfanti, S., Mori, E., Tonini, G., Lonardi, S., Fontanini, G., Boni, L., and Falcone, A.

Published
2018
Full Text
View/download PDF

46. O-007 - Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

Author

Rossini, D., Cremolini, C., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Bergamo, F., Danesi, R., Cardellino, G., Tamburini, E., Dell'Aquila, E., Strippoli, A., Masi, G., Tonini, G., Negri, F., Corsi, D., Pella, N., Intini, R., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

47. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.

Author

Dell'Aquila, E, Cremolini, C, Zeppola, T, Lonardi, S, Bergamo, F, Masi, G, Stellato, M, Marmorino, F, Schirripa, M, and Urbano, F

Subjects
*NEUTROPHILS, *LYMPHOCYTES, *COLON cancer, *BEVACIZUMAB, *PROGRESSION-free survival, *UNIVARIATE analysis
Abstract

Background: Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial. Patients and methods: Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR<3) versus high (NLR≥3) NLR, as primary analysis. As secondary analysis, NLR was treated as an ordinal variable with three levels based on terciles distribution. Results: NLR at baseline was available for 413 patients. After multiple imputation at univariate analysis, patients with high NLR had significantly shorter progression-free survival (PFS) [hazard ratio (HR) 1.27 (95% CI 1.05-1.55), P=0.017] and overall survival (OS) [HR 1.56 (95% CI 1.25-1.95), P<0.001] than patients with low NLR. In the multivariable model, NLR retained a significant association with OS [HR 1.44 (95% CI 1.14-1.82), P=0.014] but not with PFS [HR 1.18 (95% CI 0.95-1.46), P=0.375]. No interaction effect between treatment arm and NLR was evident in terms of PFS (P for interaction=0.536) or OS (P for interaction=0.831). Patients with low [HR 0.84 (95% CI 0.64-1.08)] and high [HR 0.73 (95% CI 0.54-0.97)] NLR achieved similar PFS benefit from the triplet and consistent results were obtained in terms of OS [HR 0.83 (95% CI 0.62-1.12) for low NLR; HR 0.82 (95% CI 0.59-1.12) for high NLR]. Conclusion: This study confirmed the prognostic role of NLR in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR. The advantage of the triplet is independent of NLR at baseline. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib

Author

Antoniotti, C., primary, Loupakis, F., additional, Schirripa, M., additional, Cremolini, C., additional, Poliseno, L., additional, Salvatore, L., additional, Tuccoli, A., additional, D'Aurizio, R., additional, Marmorino, F., additional, Borelli, B., additional, Rossini, D., additional, Saettini, A., additional, Gini, S., additional, Moretto, R., additional, Rizzo, I., additional, Dell'Aquila, E., additional, Pellegrini, M., additional, and Falcone, A., additional

Published
2015
Full Text
View/download PDF

50. A20 - Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO

Author

Santini, D., Cremolini, C., Salvatore, L., Lonardi, S., Dell'Aquila, E., Cattaneo, M., Loupakis, F., Rossini, D., Vincenzi, B., Ziampiri, S., Buoro, V., Tamburini, E., Basile, D., Corsi, D.C., Fioroni, I., Masi, G., Borelli, B., Del Re, M., Tonini, G., and Falcone, A.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results